15731-41-6Relevant articles and documents
Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(II) and copper(II) complexes
Di Vaira, Massimo,Bazzicalupi, Carla,Orioli, Pierluigi,Messori, Luigi,Bruni, Bruno,Zatta, Paolo
, p. 3795 - 3797 (2004)
Clioquinol, a 8-hydroxyquinoline derivative, is producing very encouraging results in the treatment of Alzheimer's disease (AD). Its biological effects are most likely ascribed to complexation of specific metal ions, such as copper(II) and zinc(II), critically associated with protein aggregation and degeneration processes in the brain. We report here, for the first time, a structural characterization of the zinc(II) and copper(II) complexes of clioquinol. A ligand to metal stoichiometry of 2:1 is found in both cases, though in the presence of quite different coordination polyhedra. The present findings are discussed in the frame of modern approaches to AD treatment.
Theoretical and experimental studies on the fluorescence properties of aluminum(III), cadmium(II), zinc(II), and copper(II) complexes of substituted 8-hydroxyquinoline
Hongli, Chen,Hongrui, Cheng,Menglin, Ma,Qingrong, Sun,Weiqing, Yang,Yuanyuan, Zhang
, p. 623 - 634 (2020/12/14)
Fifty-five 8-hydroxyquinoline (8-HQ) derivatives are synthesized and the corresponding aluminum(III), cadmium(II), copper(II), and zinc(II) metal complexes are prepared and their fluorescent activities are evaluated. The results indicate that the aluminum complexes have the best fluorescence properties, followed by zinc and cadmium complexes, while almost no fluorescence is observed with the copper complexes. The relationship between the fluorescence properties and complex structure is summarized and a predictive three-dimensional quantitative structure–property relationship model is established using the multifit molecular alignment rule of Sybyl program. With the introduction of groups at the C-2 position or electron-withdrawing groups to the 8-hydroxyquinoline framework, fluorescence wavelength blue shifts are observed with the zinc, aluminum, and cadmium complexes. At the same time, a red shift of the fluorescence emission wavelength is detected for the aluminum and zinc complexes when C-5 of 8-hydroxyquinoline was substituted with halogens or a methyl group. Moreover, the zinc, cadmium, and aluminum complexes with 2,4-dimethyl substituents on the 8-hydroxyquinoline all show good fluorescence properties. The highest occupied molecular orbital and lowest unoccupied molecular orbital energies of the complexes are also calculated and the fluorescence properties of the metal complexes are analyzed from the viewpoint of molecular orbitals.
Solution Chemistry of Copper(II) Binding to Substituted 8-Hydroxyquinolines
Dolgova, Natalia V.,George, Graham N.,Harris, Hugh H.,James, Ashley K.,Kroll, Thomas,Pickering, Ingrid J.,Pushie, M. Jake,Sokaras, Dimosthenis,Sopasis, George J.,Summers, Kelly L.
, p. 13858 - 13874 (2020/10/09)
8-Hydroxyquinolines (8HQs) are a family of lipophilic metal ion chelators that have been used in a range of analytical and pharmaceutical applications over the last 100 years. More recently, CQ (clioquinol; 5-chloro-7-iodo-8-hydroxyquinoline) and PBT2 (5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxyquinoline) have undergone clinical trials for the treatment of Alzheimer's disease and Huntington's disease. Because CQ and PBT2 appear to redistribute metals into cells, these compounds have been redefined as copper and zinc ionophores. Despite the attention surrounding the clinical trials and the clear link between 8HQs and metals, the fundamental solution chemistry of how these compounds bind divalent metals such as copper and zinc, as well as their mechanism(s) of action in mammalian systems, remains poorly understood. In this study, we used a combination of X-ray absorption spectroscopy (XAS), high-energy resolution fluorescence detected (HERFD) XAS, electron paramagnetic resonance (EPR), and UV-visible absorption spectroscopies to investigate the aqueous solution chemistry of a range of 8HQ derivatives. To circumvent the known solubility issues with 8HQ compounds and their complexes with Cu(II), and to avoid the use of abiological organic solvents, we have devised a surfactant buffer system to investigate these Cu(II) complexes in aqueous solution. Our study comprises the first comprehensive investigation of the Cu(II) complexes formed with many 8HQs of interest in aqueous solution, and it provides the first structural information on some of these complexes. We find that halogen substitutions in 8HQ derivatives appear to have little effect on the Cu(II) coordination environment; 5,7-dihalogenated 8HQ conformers all have a pseudo square planar Cu(II) bound by two quinolin-8-olate anions, in agreement with previous studies. Conversely, substituents in the 2-position of the 8HQ moiety appear to cause significant distortions from the typical square-planar-like coordination of most Cu(II)-bis-8HQ complexes, such that the 8HQ moieties in the Cu(II)-bis-8HQ complex are rotated approximately 30-40° apart in a propeller-like arrangement.
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
Wehbe, Mohamed,Lo, Cody,Leung, Ada W. Y.,Dragowska, Wieslawa H.,Ryan, Gemma M.,Bally, Marcel B.
, p. 682 - 690 (2017/10/06)
Insensitivity to platinum, either through inherent or acquired resistance, is a major clinical problem in the treatment of many solid tumors. Here, we explored the therapeutic potential of diethyldithiocarbamate (DDC), pyrithione (Pyr), plumbagin (Plum), 8-hydroxyquinoline (8-HQ), clioquinol (CQ) copper complexes in a panel of cancer cell lines that differ in their sensitivity to platins (cisplatin/carboplatin) using a high-content imaging system. Our data suggest that the copper complexes were effective against both platinum sensitive (IC50?~?1?μM platinum) and insensitive (IC50?>?5?μM platinum) cell lines. Furthermore, copper complexes of DDC, Pyr and 8-HQ had greater therapeutic activity compared to the copper-free ligands in all cell lines; whereas the copper-dependent activities of Plum and CQ were cell-line specific. Four of the copper complexes (Cu(DDC)2, Cu(Pyr)2, Cu(Plum)2 and Cu(8-HQ)2) showed IC50 values less than that of cisplatin in all tested cell lines. The complex copper DDC (Cu(DDC)2) was selected for in vivo evaluation due to its low nano-molar range activity in vitro and the availability of an injectable liposomal formulation. Liposomal (Cu(DDC)2) was tested in a fast-growing platinum-resistant A2780-CP ovarian xenograft model and was found to achieve a statistically significant reduction (50%; p??0.05) in tumour size. This work supports the potential use of copper-based therapeutics to treat cancers that are insensitive to platinum drugs.
Copper-dependent cytotoxicity of 8-hydroxyquinoline derivatives correlates with their hydrophobicity and does not require caspase activation
Tardito, Saverio,Barilli, Amelia,Bassanetti, Irene,Tegoni, Matteo,Bussolati, Ovidio,Franchi-Gazzola, Renata,Mucchino, Claudio,Marchiò, Luciano
, p. 10448 - 10459 (2013/02/23)
This study reports the structure-activity relationship of a series of 8-hydroxoquinoline derivatives (8-HQs) and focuses on the cytotoxic activity of 5-Cl-7-I-8-HQ (clioquinol, CQ) copper complex (Cu(CQ)). 8-HQs alone cause a dose-dependent loss of viability of the human tumor HeLa and PC3 cells, but the coadministration of copper increases the ligands effects, with extensive cell death occurring in both cell lines. Cytotoxic doses of Cu(CQ) promote intracellular copper accumulation and massive endoplasmic reticulum vacuolization that precede a nonapoptotic (paraptotic) cell death. The cytotoxic effect of Cu(CQ) is reproduced in normal human endothelial cells (HUVEC) at concentrations double those effective in tumor cells, pointing to a potential therapeutic window for Cu(CQ). Finally, the results show that the paraptotic cell death induced by Cu(CQ) does not require nor involve caspases, giving an indication for the current clinical assessment of clioquinol as an antineoplastic agent.
